CClinicalTrials.gg
CompletedNCT07129408EpiMentDisSKUpdated Feb 18, 2026

Epidemiological Study on the Prevalence of Mental Disorders in Slovakia

An observational study in Depression Disorders, Bipolar Affective Disorder and Generalized Anxiety Disorder (GAD), sponsored by Comenius University. Completed at 1 site in Slovakia. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-18.

Sponsored by Comenius University · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
3,100
Ages
18 Years and older
Sex
All
01

Study summary

This study maps the current epidemiological situation of mental disorders in Slovakia. The aim of the study is to determine the prevalence of selected mental disorders in the adult population of the Slovak Republic, assess the availability and use of mental health care services, evaluate the impact of symptoms of selected mental disorders on quality of life and functional capacity, and identify population groups at the highest risk of not using available services despite the presence of mental disorders.

The proposed project will provide unique data that have not yet been available in Slovakia on the prevalence of the most common mental disorders in the adult population in relation to age, gender, level of education, and broader social and economic contexts. It will also offer insights into the relationship between risk factors and the onset and course of these mental disorders, their overall societal impact, and the use or absence of mental health care services.

Read the detailed description

Examining the current prevalence of mental disorders in the Slovak population will allow for the accurate identification of population groups who, despite experiencing symptoms of mental disorders, do not utilize mental health care services. As a result, these individuals often experience reduced functionality and a diminished quality of life. According to expert estimates, this group may include 60-80% of people with symptoms of mental disorders. However, only a population-based study that comprehensively maps this issue can provide a clear and accurate picture of the situation.

This survey on the prevalence of mental disorders and their associated risk factors will be conducted as a cross-sectional study using the internationally recognized and standardized Mini International Neuropsychiatric Interview (MINI).

The MINI instrument will be administered first to 100 respondents in a pilot phase and then to a representative sample of 3,000 respondents. Participants will be selected using a multistage sampling method that covers the entire adult population of the Slovak Republic. The selection process and data collection will be conducted by a professional research agency.

The sample size has been carefully calculated to ensure that the results are generalizable to the entire adult population of Slovakia, with a 95% confidence interval and a 2% margin of error. This representative sample will make it possible to gather sufficient data even on the least common mental disorders (with a prevalence of around 1%), ensuring that the findings are both meaningful and statistically robust.

Data collection will take place through face-to-face interviews conducted by trained interviewers from the research agency, all of whom will receive specialized training in administering the MINI tool. The data will then be subject to in-depth analysis and interpretation by experts in epidemiology, clinical psychology, sociology, and psychiatry. This multidisciplinary evaluation will serve as the foundation for developing recommendations for key ministries - including those responsible for health, education, family, and social affairs - as well as for other sectors of society. The results will also be internationally comparable, as they will align with data collected using the same methodology in other countries.

The analysis of the collected data will help identify unmet needs in mental health care, support improvements in the care of individuals with mental disorders, guide the development of a comprehensive care network, highlight at-risk population groups, and inform targeted prevention strategies.

Ultimately, this study will generate unique data - previously unavailable in Slovakia - on the prevalence of the most common mental disorders in the adult population, with regard to age, gender, educational level, and broader social and economic factors. It will also provide valuable insights into the relationship between risk factors and the development and course of mental disorders, their overall impact on society, and the accessibility and utilisation of mental health care services.

02

Conditions studied

  • Depression Disorders
  • Bipolar Affective Disorder
  • Generalized Anxiety Disorder (GAD)
  • Panic Disorder
  • Agoraphobia
  • Social Phobia
  • Obsessive Compulsive Disorder (OCD)
  • Posttraumatic Stress Disorder (PTSD)
  • Alcohol Addiction
  • Anorexia Nervosa
  • Bulimia Nervosa

Keywords

  • Mental disorder prevalence
  • Slovak Republic
  • Mental Health
  • Population study
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Adult population of Slovak Republic

Inclusion criteria

  • age 18 years or older
  • ability and willingness to undergo a face-to-face interview with an interviewer, to answer interviewer's questions from a questionnaire
  • signing an informed consent

Exclusion criteria

Exclusion Criteria:

  • less tan 18 years
04

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
3,100 participants (actual)
Patient registry
No
05

What researchers measure

Primary outcomes

  1. Prevalence of selected mental disorders in the Slovak Republic assessed by the Mini-International Neuropsychiatric Interview

    The current and lifetime prevalence of mental disorders in the Slovak population will be determined based on respondents' answers using the standardised and internationally recognised questionnaire tool, the Mini-International Neuropsychiatric Interview (MINI). Lifetime and current population prevalence and treated prevalence will be determined by age, sex, educational attainment, overall health status, social and economic determinants.

    Time frame: From the end of enrolment within 6 months

06

Study locations

1 site
  • Ministry of Health of the Slovak Republic
    Bratislava, 83101, Slovakia
07

References and documents

08

Registry details

Key details

Study ID
NCT07129408
Lead sponsor
Comenius University
Collaborators
European Union, European Commission
Responsible party
Alexandra Brazinova (Chair of Institute of Epidemiology, Faculty of Medicine, Comenius University) — Principal investigator
First posted
Aug 19, 2025
Start date
Feb 13, 2025
Primary completion
Jun 27, 2025
Completion
Oct 31, 2025
Last update
Feb 18, 2026

Study contacts

Alexandra Brazinova, prof. MD PhD
principal investigator · Comenius University, Faculty of Medicine, Institute of Epidemiology
Michal Hajduk, assoc.prof. PhD
study chair · Comenius University, Faculty of Arts, Department of Psychology
Maria Kralova, assoc.prof. MD PhD
study chair · Comenius University, Faculty of Medicine, Department of Psychiatry
Marek Majdan, prof. MS PhD
study chair · Trnava University, Faculty of Health Care and Social Work

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion